Get the Stockscreener App
11.69
2.18%
-0.26
Omeros Corporation stock is traded at $11.69, with a volume of 1.35M.
It is down -2.18% in the last 24 hours and down -31.07% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$11.95
Open:
$11.84
24h Volume:
1.35M
Relative Volume:
0.55
Market Cap:
$828.83M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-6.2181
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-2.01%
1M Performance:
-31.07%
6M Performance:
+203.64%
1Y Performance:
+32.24%
1-Day Range:
$11.61
$12.17
1-Week Range:
$11.45
$12.68
52-Week Range:
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
11.69 | 847.26M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Is Omeros Corporation gaining market shareJuly 2025 Gainers & Safe Entry Momentum Stock Tips - mfd.ru
Omeros begins commercial distribution of TA-TMA treatment Yartemlea By Investing.com - Investing.com Australia
Big Money Moves: What is the implied volatility of Air Products and Chemicals IncWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn
Omeros (OMER) Rises on First Shipments of Yartemlea - GuruFocus
Omeros wins first commercial sales of Yartemlea (OMER:NASDAQ) - Seeking Alpha
OMER: D. Boral Capital Maintains Buy Rating with $36 Price Targe - GuruFocus
Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital - MarketBeat
Omeros stock rises as first commercial YARTEMLEA shipments begin By Investing.com - Investing.com South Africa
Omeros stock rises as first commercial YARTEMLEA shipments begin - Investing.com
Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA - GuruFocus
Omeros announces first commercial sales of Yartemlea - TipRanks
Omeros begins commercial distribution of TA-TMA treatment Yartemlea - Investing.com
Omeros Announces First Commercial Sales of YARTEMLEA® - Yahoo Finance
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com
Omeros wins FDA nod for transplant therapy - MSN
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Portfolio Update: Can Omeros Corporation maintain sales growthJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Growth Value: Should you buy the dip on Omeros CorporationQuarterly Growth Report & Fast Gain Stock Tips - baoquankhu1.vn
Omeros Shares Face Headwinds Amid Mixed Signals - AD HOC NEWS
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
Omeros (NASDAQ:OMER) Shares Down 5.8% Following Insider Selling - MarketBeat
Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares - MarketBeat
Omeros (OMER) Price Target Increased by 29.70% to 44.54 - Nasdaq
Omeros VP Borges sells $750k in shares By Investing.com - Investing.com Nigeria
Omeros VP Borges sells $750k in shares - Investing.com
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - msn.com
HC Wainwright Has Bearish Outlook for Omeros FY2026 Earnings - MarketBeat
Why did Omeros stock jump 5% in after-hours trading today? - MSN
Omeros (OMER) Price Target Increased by 12.22% to 34.34 - MSN
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN
Will Omeros Corporation stock see insider buyingRecovery Day Options & size guide reminders to avoid returns - Улправда
Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen - MarketBeat
Omeros Details Yarcomlia U.S. Launch After FDA Approval, Pricing and Supply Outlook in Focus - MarketBeat
What is HC Wainwright's Forecast for Omeros Q1 Earnings? - MarketBeat
Fundamentals Check: Will Omeros Corporation stock see insider buyingMarket Growth Report & Daily Stock Momentum Reports - Улправда
Why Omeros Corporation stock could benefit from AI revolutionJuly 2025 Technicals & Growth-Oriented Investment Plans - Улправда
Why retail investors pile into Omeros Corporation stock2025 Sector Review & Technical Entry and Exit Tips - ulpravda.ru
Omeros (NASDAQ:OMER) Trading Up 10.3% on Analyst Upgrade - MarketBeat
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set - TechStock²
OMER: HC Wainwright & Co. Raises Price Target to $40 with Buy Ra - GuruFocus
OMER's Rating Maintained as 'Buy' with $36 Price Target by Analyst | OMER Stock News - GuruFocus
Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros - TipRanks
Omeros (NASDAQ:OMER) Price Target Raised to $40.00 - MarketBeat
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):